Science
Mechanism of Action
This extract modulates skin health through several pathways. It exhibits anti-inflammatory effects by decreasing proinflammatory cytokines such as PGE2, LTB4, IL-1β, IL-4, IL-5, IFN-γ, and IL-12, effectively blocking the Syk/NF-κB pathway crucial in inflammatory processes. Its antimicrobial and antibacterial properties are attributed to naphthoquinones, which disrupt bacterial cell wall synthesis, membrane integrity, and nucleic acid synthesis. Additionally, the extract provides significant antioxidant protection and its components, particularly beta-lapachone, show potential as depigmentation agents for hyperpigmentation.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 In vitro, the extract demonstrated significant antioxidant activity in the DPPH experiment, achieving an IC50 of approximately 12.13 ± 0.53 µg/ml.
- 02 It exhibited antibacterial action against various bacterial strains, with minimum inhibitory concentrations (MIC) ranging from 3.67 ± 1.15 to 5.83 ± 0.76 mg/mL.
- 03 Oral administration of a Tabebuia avellanedae ethanol extract (Ta-EE) in mice (60, 120, and 240 mg/kg) ameliorated atopic dermatitis symptoms, protected skin from damage and epidermal thickening, and reduced allergic and proinflammatory cytokine levels (histamine, IgE, IL-4, IFN-γ) without observed toxicity.
Transparency
Dusting Analysis
Given the ingredient's 'not reviewed' CIR status and 'unknown' rating on INCIDecoder, it is not yet widely recognized or standardized in cosmetic formulations. This suggests it is less likely to be included at sub-efficacious concentrations for marketing claims.
The Formula
Formulation
Stability
Aqueous and ethanol extracts are commonly investigated, suggesting good solubility in polar solvents. However, beta-lapachone, a key component, is noted for its low water solubility (160 µM) and poor stability. Optimal pH ranges for the stability of the overall extract in cosmetic formulations are not available.
Safety
Safety Profile
Acute toxicity studies in mice indicated a low toxicity profile. An ethanol extract (Ta-EE) effectively ameliorated atopic dermatitis symptoms in mice without any observed toxicity. An oral dose of 1050 mg/day was generally safe and well-tolerated in a human clinical trial for primary dysmenorrhea. However, specific CIR, SCCS, or FDA status for cosmetic use has not been established.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Tabebuia Avellanedae Bark Extract presents as a valuable ingredient due to its proven antioxidant, anti-inflammatory, and antimicrobial properties, coupled with promising depigmentation potential and a favorable safety profile in preliminary studies.
Related
Similar Ingredients
Finding similar ingredients…